Evotec consensus picture on Wall Street, shares trade as ADR on NASDAQ
30.06.2026 - 13:49:37 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:49.
Evotec (DE0005664809) trades in the US as an ADR on NASDAQ under the ticker EVO, giving the Hamburg-based biotech services group direct access to Wall Street investors. The consensus backdrop on the stock reflects a mix of cautious and constructive views after a period of strategic adjustments and management changes.
What recent updates show
According to a detailed overview of Evotec news and data, the EVO ADR last traded at about $2.79 on June 29, 2026, implying a market capitalization of roughly $973 million. This places Evotec in the small to mid cap bracket among drug discovery service peers such as Charles River Laboratories and Syneos Health.
The same source highlights several operational announcements in recent months, including the appointment of Dr. Ingrid Müller as Chief Operating Officer effective May 1, 2026, and a strengthening of Evotec’s AI-led discovery capabilities with Rui Wang becoming Executive Vice President, Head of Global In Silico and AI from June 2, 2026. These changes underscore the group’s push to anchor its service portfolio more deeply in data-driven and computational platforms.
Analyst and investor focus on Evotec
Market commentary aggregating broker views on Evotec indicates that analysts on NASDAQ follow the stock with an eye on revenue growth in its drug discovery alliances, margin trends in biologics manufacturing, and cash generation from milestone payments. Ratings span from Hold to Buy, with some firms flagging execution risks around long development cycles typical in outsourced R&D, while others point to the breadth of Evotec’s partner base as a stabilizing factor.
In investor notes, Evotec is often compared with other contract research and development organizations, with a particular focus on its ability to leverage proprietary platforms like PanOmics and Molecular Patient Databases to win repeat business. For US-based investors, the NASDAQ listing and ADR structure simplify access to the stock versus its primary Frankfurt listing, while currency considerations remain part of the valuation discussion given Evotec’s euro cost base and global revenue mix.
All news and analysis on the Evotec shares
Further company reports, consensus data and regulatory filings on Evotec are available in the dedicated topic section and on the Investor Relations page.
The business behind Evotec
Evotec generates most of its income by providing research and development services across the drug discovery and early development chain, working under multi year agreements with pharmaceutical, biotech and academic partners. Its offerings span target discovery, hit identification, lead optimization and preclinical development, including both small molecule and biologics projects.
In addition, Evotec co owns or co finances selected therapeutic programs with partners, sharing development risk and potential future milestone and royalty streams. Platforms such as its integrated PanOmics suite and iPSC-based disease modeling tools are marketed as differentiators that can shorten discovery timelines and improve success rates, which is central to the value proposition in discussions with investors.
Where the stock trades today
Evotec shares (DE0005664809) trade on NASDAQ in the form of ADRs under the ticker EVO, with a last quoted price of $2.79 as of June 29, 2026. The ADR structure allows US investors to access the company’s equity directly in dollars while underlying operations remain largely euro based.
Evotec key share data
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVO
- Trading venue: NASDAQ (ADR)
- Price (as of 2026-06-29, 00:00): 2.79 USD
- Market cap: 973.2 million USD (as of 2026-06-29)
- Sector / industry: Biotechnology / Drug discovery services
- Index membership: None of the major headline indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data are based on sources believed to be reliable at the time of writing but may change without notice.
